8-K: 60 Degrees Pharma Regains Nasdaq Compliance, Averts Delisting

60 Degrees Pharmaceuticals, Inc. announced it has regained compliance with Nasdaq's minimum bid price requirement, averting a delisting.

Summary

• 60 Degrees Pharmaceuticals, Inc. received a written notice on January 20, 2026, from Nasdaq regarding a determination to delist its common stock and warrants.
• The delisting notice was due to the company's failure to maintain a minimum bid price of $1.00 per share for 30 consecutive business days, violating Nasdaq Listing Rule 5550(a)(2).
• The company paid a $20,000 hearing fee and requested an appeal, which temporarily stayed the suspension of trading and the filing of Form 25-NSE.
• On February 11, 2026, Nasdaq Listing Qualifications Staff notified the company that it had regained compliance with the minimum bid price requirement.
• As a result, the hearing before the Nasdaq Hearings Panel, previously scheduled for February 19, 2026, has been cancelled, and the matter is now closed.
• The company's common stock and warrants will continue to be listed and traded on The Nasdaq Capital Market.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong positive development, as the company successfully resolved a significant compliance issue that could have severely impacted its market standing and investor confidence.

Positives

• Regained compliance with Nasdaq's minimum bid price requirement, resolving a significant listing issue.
• Averted delisting from The Nasdaq Capital Market, preserving market access and liquidity.
• The scheduled Nasdaq Hearings Panel hearing has been cancelled, removing immediate regulatory uncertainty.
• The matter is now closed, indicating a stable listing status moving forward.
• Common stock and warrants will continue to be listed and traded on The Nasdaq Capital Market.

Negatives

• Received a delisting notice from Nasdaq on January 20, 2026, indicating a period of non-compliance.
• Failed to maintain a minimum bid price of $1.00 per share for 30 consecutive business days.
• Incurred a $20,000 hearing fee as part of the appeal process.

Risks

• Initial risk of delisting from The Nasdaq Capital Market due to non-compliance with the minimum bid price rule.
• Potential loss of investor confidence and reduced liquidity if delisting had occurred.

Future Outlook

The Company's common stock will continue to be listed and traded on The Nasdaq Capital Market, indicating stability in its listing status.

Management Comments

• The registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. (Signed by Geoffrey Dow, Chief Executive Officer and President)

Industry Context

StockSavvy.ai notes that maintaining Nasdaq listing compliance is critical for public companies, as it ensures liquidity, investor visibility, and access to capital markets. Failure to meet listing standards, such as the minimum bid price, can lead to significant challenges in attracting and retaining investors, often resulting in a move to over-the-counter markets with reduced trading volume and investor interest. Regaining compliance, as 60 Degrees Pharmaceuticals has done, is a positive signal for market stability and investor confidence.

Comparison to Industry Standards

• Maintaining a minimum bid price of $1.00 is a standard requirement across major U.S. exchanges like Nasdaq and NYSE for continued listing.
• Companies such as Sorrento Therapeutics (SRNEQ) and Bed Bath & Beyond (BBBYQ) faced similar delisting issues due to bid price non-compliance, often leading to significant share price volatility and eventual delisting or bankruptcy.
• 60 Degrees Pharmaceuticals' successful resolution contrasts with these examples, demonstrating effective management of listing requirements.

Stakeholder Impact

• Shareholders: Positive impact as the risk of delisting is removed, preserving liquidity and market access for their shares.
• Investors: Increased confidence due to the company's ability to resolve compliance issues and maintain its Nasdaq listing.

Next Steps

• Continued listing and trading of common stock and warrants on The Nasdaq Capital Market.

Key Dates

Recommendation

While regaining Nasdaq compliance is a significant positive, it primarily removes a downside risk rather than indicating fundamental operational improvements or growth. The company was previously in a precarious position, and while this resolution is good, it doesn't inherently suggest a strong 'buy' signal without further positive operational news. A 'hold' recommendation is appropriate as the immediate threat is gone, but new catalysts are needed for significant upside.

Keywords

Nasdaq, compliance, delisting, minimum bid price, 60 Degrees Pharmaceuticals, SXTP, stock market, listing requirements, corporate governance, pharmaceutical